Proton pump inhibitor improves breath marker in moderate asthma with gastroesophageal reflux disease.
BACKGROUND
Gastroesophageal reflux disease (GERD) influences the symptoms of asthma with acid and oxidative stress.


OBJECTIVE
The purpose of this study was to determine the usefulness of measurement of the acid stress marker pH and the oxidative stress marker 8-isoprostane by exhaled breath condensate in proton pump inhibitor (PPI) therapy effect on moderate asthma patients with GERD.


METHODS
The pH and the concentration of 8-isoprostane were measured in the exhaled breath condensate of patients with moderate asthma (n = 36) and healthy subjects (n = 26). Two months of PPI therapy (lansoprazole at 30 mg/day) were done in the asthma patients with (n = 13) or without (n = 13) GERD according to a questionnaire for the diagnosis of reflux disease, and exhaled markers were measured.


RESULTS
The pH was lower (7.3 +/- 0.3) and the 8-isoprostane level was higher (27.7 +/- 2.3) in the asthma patients than in the healthy control subjects (pH 7.5 +/- 0.2 and 8-isoprostane 6.6 +/- 1.2). Two months of PPI therapy improved the pH (from 7.2 +/- 0.1 to 7.3 +/- 0.1) and the 8-isoprostane concentration (from 32.7 +/- 3.4 to 19.2 +/- 3.4) in the asthma patients with GERD, along with improvement of GERD symptoms. However, these markers did not change in the asthma patients without GERD.


CONCLUSIONS
Measurement of the pH and 8-isoprostane level of exhaled breath condensate may be useful to evaluate the influence of GERD on asthma, as well as to determine the timing of intermittent PPI therapy.
Shimizu
Yasuo
Y
Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Gunma, Japan. yasuos@med.gunma-u.ac.jp
Dobashi
Kunio
K
Zhao
Jian Jun
JJ
Kawata
Tadayoshi
T
Ono
Akihiro
A
Yanagitani
Noriko
N
Kaira
Kyoichi
K
Utsugi
Mitsuyoshi
M
Hisada
Takeshi
T
Ishizuka
Tamotsu
T
Mori
Masatomo
M
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000494:pharmacology* / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy / Q000453:epidemiology*; D015415:Biomarkers / Q000032:analysis; D001944:Breath Tests; D015897:Comorbidity; D015237:Dinoprost / Q000031:analogs & derivatives / Q000032:analysis; D005260:Female; D005764:Gastroesophageal Reflux / Q000453:epidemiology*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress; D054328:Proton Pump Inhibitors
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D015415:Biomarkers; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; C075750:8-epi-prostaglandin F2alpha; D015237:Dinoprost